Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

"We are pleased with the advances made over the past 15 months at Argos. We completed two successful financings, a Series E financing in 2013 and an initial public offering last month, raising an aggregate of that we expect will enable us to complete the pivotal Phase 3 ADAPT trial of our lead product candidate, AGS-003, in metastatic renal cell ... (more)

http://ift.tt/1rIakdX